Results 151 to 160 of about 67,431 (260)

From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia. [PDF]

Leukemia
Hochhaus A, Talpaz M, Saglio G, Cortes JE, Hughes T, Apperley J, Hantschel O, Rea D, Schuld P, Kantarjian H.   +9 more
europepmc   +1 more source

Oral Lesions Developed in Post‐Hematopoietic Stem Cell Transplant Patients and the Role of Cryogun Cryotherapy

Clinical and Experimental Dental Research, Volume 12, Issue 3, June 2026.
ABSTRACT Objective To investigate the development of oral premalignant and malignant lesions as a major long‐term complication following hematopoietic stem cell transplantation. Methods This single‐center retrospective study identified 17 patients who developed 26 pathology‐confirmed oral premalignant and malignant lesions after hematopoietic stem cell
Pei Hsuan Lu, Kelly Yi Ping Liu, Samson P. Ng, Catherine F. Poh   +3 more
wiley   +1 more source

First case report of hypouricemia associated with adjuvant imatinib therapy in a patient with small intestinal gastrointestinal stromal tumor. [PDF]

Front Oncol
Bu J, Mahan Y, Yuemaier R, Zhang X, Zhou L.   +4 more
europepmc   +1 more source

A scoping review of imatinib-induced testicular toxicity and male fertility impairment. [PDF]

Front Endocrinol (Lausanne)
Ji X, Ahmad MF, Mokhtar MH, He X, Abdul Karim AK.   +4 more
europepmc   +1 more source

A comprehensive analysis of the adverse drug events of metastatic and unresectable gastrointestinal stromal tumor treatment options: avapritinib, imatinib, regorafenib, ripretinib, and sunitinib safety insights and implications. [PDF]

Future Sci OA
Thompson CM, Andrews MB, Adler DG.
europepmc   +1 more source

Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro [PDF]

, 2012
Lyons, John, Holyoake, Tessa L., Jorgensen, Heather, Shah, Mohsin, Gallipoli, Paolo   +4 more
core   +1 more source

Characterizing P-glycoprotein and Breast Cancer Resistance Protein interactions of asciminib among other tyrosine kinase inhibitors used in chronic myeloid leukemia. [PDF]

Cancer Chemother Pharmacol
Verhagen NE, Touw DCW, van den Heuvel JJMW, van den Broek PH, Blijlevens NMA, Janssen JJWM, Koenderink JB, Russel FGM.   +7 more
europepmc   +1 more source

Integrating Single‐Cell and Spatial Transcriptomes in HGSOC to Decipher the Metastasis‐Associated Biomarkers

iNew Medicine, Volume 2, Issue 2, June 2026.
ABSTRACT High‐grade serous ovarian cancer (HGSOC) is the most common and lethal histological subtype of ovarian cancer. This study aimed to identify peritoneal metastasis‐associated biomarkers of HGSOC to provide directions for subsequent treatment. Transcriptome data were extracted from the GEO database and literature. Differential expression analysis,
Jing Zhu, Zhicheng Yu, Yang Zhang, Hui Hong, Xiaoli Wang, Shan Jiang, Ying Zhou, Cheng Peng, Hongbo Chen   +8 more
wiley   +1 more source

Roles of extracellular vesicles in the pathogenesis of chronic myeloid leukemia. [PDF]

J Physiol Biochem
Hrdinova T, Kupcova Skalnikova H.
europepmc   +1 more source

Vacuolization as a Novel Approach to Cancer Therapy

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 6, June 2026.
This review discusses the novel strategy of inducing vacuole formation in cancer cells using small molecules, that induce nonapoptotic cell death mechanisms, such as paraptosis, oncosis, autophagy, and methuosis, and its potential in overcoming resistance to apoptosis‐based cancer therapies.
Mariah Pasternak, Noor Hussein, Veronica Piedra, Saloni Malla, Chandrabose Karthikeyan, Haneen Amawi, Harish Rajak, Charles R. Ashby Jr., R. Jayachandra Babu, Amit K. Tiwari   +9 more
wiley   +1 more source